Clinical efficacy of the rotation of phototherapy methods (PUVA therapy and mid-wavelength ultraviolet therapy (311 nm)) in patients with moderate to severe forms of psoriasis

Goal. To assess the therapeutic efficacy of the rotation of mid-wavelength ultraviolet therapy (311 nm) and PUVA therapy in patients with moderate to severe forms of psoriasis, and to assess the efficacy of mid-wavelength ultraviolet therapy (311 nm) in a multiple-course therapy. Materials and methods. The study involved 66 patients with moderate to severe forms of psoriasis who received multiple courses of treatment by methods of the PUVA therapy and narrowband mid-wavelength phototherapy (311 nm). The patients were divided into three groups: Group 1 (n = 20) - patients who received treatment in the form of mid-wavelength ultraviolet therapy (311 nm) after multiple courses of PUVA therapy; Group 2 (n = 26) - patients who received only multiple courses of PUVA therapy; Group 3 (n = 20) - patients who received only multiple courses of mid-wavelength ultraviolet therapy (311 nm). Results. The authors determined high efficacy (82.8%) of mid-wavelength ultraviolet therapy (311 nm) in patients with moderate to severe forms of psoriasis vulgaris who had previously received multiple courses of PUVA therapy. After multiple courses of long-term treatment by mid-wavelength ultraviolet therapy (311 nm), patients with moderate to severe forms of psoriasis had high efficacy of such multiple courses of treatment (85.78%). Conclusion. Patients with moderate to severe forms of psoriasis who had previously received multiple courses of PUVA therapy can be switched to mid-wavelength ultraviolet therapy (311 nm) with the maintenance of high efficacy of such treatment. The authors observed the absence of any adaptation to the spectral range of mid-wavelength ultraviolet therapy (311 nm) in case of multiple courses of treatment.

[1]  L. Misery,et al.  Efficacy of Psoralen UV‐A therapy vs. Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  T. Tsai,et al.  Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. , 2011, Journal of dermatological science.

[3]  H. Hönigsmann,et al.  Failure of short‐term psoralen and ultraviolet A light maintenance treatment to prevent early relapse in patients with chronic recurring plaque‐type psoriasis , 2009, Photodermatology, photoimmunology & photomedicine.

[4]  A. de Silvestri,et al.  The Duration of Clinical Remission of Photochemotherapy and Narrow-Band UV-B Phototherapy in the Treatment of Psoriasis: A Retrospective Study , 2008, International journal of immunopathology and pharmacology.

[5]  Consuelo Huerta,et al.  Incidence and risk factors for psoriasis in the general population. , 2007, Archives of dermatology.

[6]  J. Hawk,et al.  Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. , 2006, Archives of dermatology.

[7]  Michael W. Taylor,et al.  Coincidence of immune‐mediated diseases driven by Th1 and Th 2 subsets suggests a common aetiology. A population‐based study using computerized General Practice data , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  S. Puig,et al.  Prevalence of psoriasis in Spain (Epiderma Project: phase I) , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  J. Ferguson,et al.  8‐MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose‐based regimen with a skin‐type approach , 1996, The British journal of dermatology.

[10]  C. Patterson,et al.  Cutaneous neoplasia following PUVA therapy for psoriasis , 1996, The British journal of dermatology.

[11]  P. Kullavanijaya,et al.  Cutaneous carcinoma and PUVA lentigines in Thai patients treated with oral PUVA , 1995, Photodermatology, photoimmunology & photomedicine.

[12]  P. Farr,et al.  Skin cancers or premalignant lesions occur in half of high‐dose PUVA patients , 1994, The British journal of dermatology.

[13]  B. Berne,et al.  Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. , 1992, Archives of dermatology.

[14]  J. Parrish,et al.  Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. , 1977, The Journal of investigative dermatology.

[15]  K. Gordon,et al.  Comparative Tolerability of Systemic Treatments for Plaque-Type Psoriasis , 2002, Drug safety.

[16]  M. Schemper,et al.  Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. , 1996, Dermatology.